COMMUNIQUÉS West-GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08/06/2024 - 14:15

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic [...]

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

08/06/2024 - 02:18

Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new [...]

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

07/06/2024 - 23:00

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, June 07, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), [...]

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07/06/2024 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

07/06/2024 - 22:18

TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ( "Spectral" or the "Company" ) (TSX: EDT) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced [...]

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

07/06/2024 - 22:05

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and [...]

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07/06/2024 - 22:05

BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/06/2024 - 22:05

BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards [...]

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/06/2024 - 22:01

BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/06/2024 - 22:01

NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/06/2024 - 22:00

CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation [...]

StateHouse Sets Date to Report Fourth Quarter and Year-End 2023 Financial Results and First Quarter 2024 Financial Results

07/06/2024 - 22:00

SAN DIEGO and TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today [...]

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

07/06/2024 - 21:32

WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday, June 6 th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN). Please note that the second paragraph has been corrected [...]

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

07/06/2024 - 19:00

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, [...]

PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024

07/06/2024 - 17:45

Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial [...]

PHAXIAM annonce les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 28 juin 2024

07/06/2024 - 17:45

Lyon (France) et Cambridge (MA, US), le 7 juin 2024 – 17h45 CEST – PHAXIAM Therapeutics (Euronext : PHXM ; FR0011471135) société biopharmaceutique qui développe des traitements innovants contre les infections [...]

Octane Medical acquires B. Braun’s global orthobiologics business

07/06/2024 - 17:27

“From the start, our corporate mission has been to make regenerative medicine the standard of care. We continue to be true to this goal, and it’s the key reason why we pursued this opportunity.” — Octane Medical Group [...]

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

07/06/2024 - 16:40

After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age 96% of Evrysdi-treated children could swallow, 80% could feed [...]

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

07/06/2024 - 15:00

CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]